Clinical Trial Update: A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 randomized study to assess the relative bioavailability of new formulations of GSK1265744 long-acting parenteral (LAP) in healthy adults. The study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cabotegravir (GSK1265744) long-acting parenteral formulation (cabotegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED